Ignite Creation Date:
2025-12-24 @ 11:24 PM
Ignite Modification Date:
2026-01-01 @ 8:31 PM
Study NCT ID:
NCT07102056
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-08-03
First Post:
2025-07-08
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
18F-AlF-NOTA-Octreotide PET in Neuroendocrine Neoplasms
Sponsor:
First Affiliated Hospital of Zhejiang University
Organization:
Study Overview
Official Title:
Prospective Study of 18F-AlF-NOTA-Octreotide PET-CT or PET-MR in Diagnosis, Treatment and Prognosis for Neuroendocrine Neoplasms
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The study aims to elucidate how 18F-Octreotide PET/CT or PET-MR can assist in accurate localization, treatment planning, prognostic predictions, and the selection of PRRT efficacy in neuroendocrine tumors. It also highlights important applications in lesion segmentation measurement, tumor grading, prognostic survival prediction, and genotype identification.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: